Journal
ACS CHEMICAL NEUROSCIENCE
Volume 6, Issue 3, Pages 398-402Publisher
AMER CHEMICAL SOC
DOI: 10.1021/cn5003557
Keywords
Alzheimer's disease; iron; size exclusion chromatography-inductively coupled plasma-mass spectrometry; transferrin; transferrin saturation
Funding
- Australian Research Council
- Australian National Health and Medical Research Council
- CRC for Mental Health
- Victorian Government's Operational Infrastructure Support program
Ask authors/readers for more resources
Plasma iron levels are decreased in Alzheimer's disease (AD) and associated with an idiopathic anemia. We examined iron-binding plasma proteins from AD patients and healthy controls from the Australian Imaging, Biomarkers and Lifestyle (AIBL) Flagship Study of Ageing using size exclusion chromatography-inductively coupled plasma-mass spectrometry. Peak area corresponding to transferrin (Tf) saturation was directly compared to routine pathological testing. We found a significant decrease in transferrin-associated iron in AD that was missed by routine pathological tests of transferrin saturation, and that was able to discriminate between AD and controls. The AD cases showed no significant difference in transferrin concentration, only a decrease in total transferrin-bound iron. These findings support that a previously identified decrease in plasma iron levels in AD patients within the AIBL study is attributable to decreased loading of iron into transferrin, and that this subtle but discriminatory change is not observed through routine pathological testing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available